Less studied AML preferentially expressed antigens include CD7, expressed on approximately 30% of patients and associated with more aggressive disease and therapy resistance [36, 37]; however, its presence on T cells, natural killer (NK) cells, and a subset of the CD34+ CD38− compartment associated with early lymphoid differentiation increases the risk of severe hematotoxicity when targeting this antigen [36, 38]. This evidence concerns the gene CD7 and acute myeloid leukemia.